Karina Andrea Gómez

Dr. Karina Andrea Gómez

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GAGonzalo R. Acevedo
Gonzalo R. Acevedo
MGMagalí C. Girard
Magalí C. Girard
KGKarina Andrea Gómez
Karina Andrea Gómez
Trypanosoma cruzi interacts with the different arms of the innate and adaptive host's immune response in a very complex and flowery manner. The history of host-parasite co-evolution has provided this protozoan with means of resisting, escaping or subverting the mechanisms of immunity and establishing a chronic infection. Despite many decades of research on the subject, the infection remains incurable, and the factors that steer chronic Chagas disease from an asymptomatic state to clinical onset are still unclear. As the relationship between T. cruzi and the host immune system is intricate, so is the amount and diversity of scientific knowledge on the matter. Many of the mechanisms of immunity are fairly well understood, but unveiling the factors that lead each of these to success or failure, within the coordinated response as a whole, requires further research. The intention behind this Review is to compile the available information on the different aspects of the immune response, with an emphasis on those phenomena that have been studied and confirmed in the human host. For ease of comprehension, it has been subdivided in sections that cover the main humoral and cell-mediated components involved therein. However, we also intend to underline that these elements are not independent, but function intimately and concertedly. Here, we summarize years of investigation carried out to unravel the puzzling interplay between the host and the parasite.

1 January 2013 in The American Journal of Pathology
Verified
Journal Article
Closed access
ISIgnacio M. Seropian
Ignacio M. Seropian
JCJuan P. Cerliani
Juan P. Cerliani
STStefano Toldo
Stefano Toldo
BTBenjamín W. Van Tassell
Benjamín W. Van Tassell
JIJuan M. Ilarregui
Juan M. Ilarregui
GRGabriel Rabinovich
Gabriel Rabinovich

15 March 2007 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
VLV. Labovsky
V. Labovsky
CSC. R. Smulski
C. R. Smulski
KGKarina Andrea Gómez
Karina Andrea Gómez
GLG. Levy
G. Levy
MLM. J. Levin
M. J. Levin

1 October 2010 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
MCMaría A. Costa
María A. Costa
MVMaría A. Lopez Verrilli
María A. Lopez Verrilli
KGKarina Andrea Gómez
Karina Andrea Gómez
PNPablo Nakagawa
Pablo Nakagawa
CPClara Peña
Clara Peña
MGMariela M. Gironacci
Mariela M. Gironacci
It has been shown that angiotensin (ANG)-(1–7) activates nitric oxide synthase (NOS) in isolated ventricular myocytes from normotensive rats. Since many ANG-(1–7) actions are enhanced in situations of increased ANG II activity, as in hypertension, in this study we investigated the in vivo effect of ANG-(1–7) on NOS activity and expression of endothelial (eNOS), neuronal (nNOS), and inducible NOS (iNOS) in ventricles from spontaneously hypertensive rats (SHR). Rats were subjected to a 60-min ANG-(1–7) infusion (0.35 nmol/min); controls received saline. NOS activity was measured using the NADPH diaphorase histochemical method and by the conversion of l-[14C]arginine to citrulline, and NOS phosphorylation and expression were determined using Western blotting. In SHR, ANG-(1–7) infusion diminished mean arterial pressure from 180 ± 9 to 146 ± 9 mmHg ( P < 0.05), and this effect was prevented by nitro-l-arginine methyl ester (l-NAME), a NOS inhibitor. In addition, NOS activity and eNOS phosphorylation were increased by ANG-(1–7) infusion. Ventricular eNOS and nNOS expression were increased 67.4 ± 6.4 and 51 ± 10%, respectively, by ANG-(1–7), whereas iNOS was not changed. In another set of experiments, we evaluated the mechanism by which ANG-(1–7) modifies NOS activity. Isolated ventricle slices preincubated with ANG-(1–7) showed an increase in NOS activity and eNOS phosphorylation, which was blocked by an AT2 and a bradykinin B2 receptor antagonist, but not by the Mas receptor antagonist. Our results show that in rats in a hypertensive state, ANG-(1–7) infusion upregulates cardiac NOS expression and activity through an AT2- and bradykinin-dependent mechanism. In this way ANG-(1–7) may elicit its cardioprotective action and contribute to some of the counterregulatory AT2 receptor effects that oppose the AT1 receptor-mediated effects.

9 October 2015 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ABAlejandro F Benatar
Alejandro F Benatar
GGGabriela A García
Gabriela A García
JBJacqeline Bua
Jacqeline Bua
JCJuan P Cerliani
Juan P Cerliani
MPMiriam Postan
Miriam Postan
KGKarina Andrea Gómez
Karina Andrea Gómez
Chronic Chagas cardiomyopathy caused by Trypanosoma cruzi is the result of a pathologic process starting during the acute phase of parasite infection. Among different factors, the specific recognition of glycan structures by glycan-binding proteins from the parasite or from the mammalian host cells may play a critical role in the evolution of the infection. Here we investigated the contribution of galectin–1 (Gal–1), an endogenous glycan-binding protein abundantly expressed in human and mouse heart, to the pathophysiology of T. cruzi infection, particularly in the context of cardiac pathology. We found that exposure of HL–1 cardiac cells to Gal–1 reduced the percentage of infection by two different T. cruzi strains, Tulahuén (TcVI) and Brazil (TcI). In addition, Gal–1 prevented exposure of phosphatidylserine and early events in the apoptotic program by parasite infection on HL–1 cells. These effects were not mediated by direct interaction with the parasite surface, suggesting that Gal–1 may act through binding to host cells. Moreover, we also observed that T. cruzi infection altered the glycophenotype of cardiac cells, reducing binding of exogenous Gal–1 to the cell surface. Consistent with these data, Gal–1 deficient (Lgals1-/-) mice showed increased parasitemia, reduced signs of inflammation in heart and skeletal muscle tissues, and lower survival rates as compared to wild-type (WT) mice in response to intraperitoneal infection with T. cruzi Tulahuén strain. Our results indicate that Gal–1 modulates T. cruzi infection of cardiac cells, highlighting the relevance of galectins and their ligands as regulators of host-parasite interactions. Galectins are a family of endogenous lectins defined by a well-conserved carbohydrate recognition domain (CRD) that recognizes β-galactoside-related glycans presented by several glycoconjugates. Up to now, fifteen galectins have been identified in a variety of cells and tissues and proposed to be crucial in diverse biological processes. Galectin–1 (Gal–1), a prototype member of the galectin family, plays key roles in pathogen recognition and in the modulation of innate and adaptive host immune responses. Following infection with the intracellular parasite Trypanosoma cruzi, the etiological agent of Chagas disease, Gal–1 was found to be up-regulated in cardiac tissue from patients with chronic Chagas cardiomyopathy. In the present study, we identified a protective role of Gal–1 in T. cruzi infection of cardiac cells, highlighting the ability of this parasite to control the glycophenotype of these cells. Our data also disclose the relevance of parasite strain-dependent differences in Gal-1-mediated control of T. cruzi infection in vivo. The findings presented here will contribute to delineate the role of Gal-1-glycan interactions during T. cruzi infection, particularly in the context of heart tissue injury, with critical implications in Chagas disease.

5 June 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SLSilvia A Longhi
Silvia A Longhi
AAAugusto Atienza
Augusto Atienza
GPGraciela Perez Prados
Graciela Perez Prados
ABAlcinette Buying
Alcinette Buying
VBVirginia Balouz
Virginia Balouz
KGKarina Andrea Gómez
Karina Andrea Gómez
Trypanosoma cruzi ribosomal P proteins, P2β and P0, induce high levels of antibodies in patients with chronic Chagas' disease Cardiomyopathy (CCC). It is well known that these antibodies alter the beating rate of cardiomyocytes and provoke apoptosis by their interaction with β1-adrenergic and M2-muscarinic cardiac receptors. Based on these findings, we decided to study the cellular immune response to these proteins in CCC patients compared to non-infected individuals. We evaluated proliferation, presence of surface activation markers and cytokine production in peripheral blood mononuclear cells (PBMC) stimulated with P2β, the C-terminal portion of P0 (CP0) proteins and T. cruzi lysate from CCC patients predominantly infected with TcVI lineage. PBMC from CCC patients cultured with P2β or CP0 proteins, failed to proliferate and express CD25 and HLA-DR on T cell populations. However, multiplex cytokine assays showed that these antigens triggered higher secretion of IL-10, TNF-α and GM-CSF by PBMC as well as both CD4+ and CD8+ T cells subsets of CCC subjects. Upon T. cruzi lysate stimulation, PBMC from CCC patients not only proliferated but also became activated within the context of Th1 response. Interestingly, T. cruzi lysate was also able to induce the secretion of GM-CSF by CD4+ or CD8+ T cells. Our results showed that although the lack of PBMC proliferation in CCC patients in response to ribosomal P proteins, the detection of IL-10, TNF-α and GM-CSF suggests that specific T cells could have both immunoregulatory and pro-inflammatory potential, which might modulate the immune response in Chagas' disease. Furthermore, it was possible to demonstrate for the first time that GM-CSF was produced by PBMC of CCC patients in response not only to recombinant ribosomal P proteins but also to parasite lysate, suggesting the value of this cytokine to evaluate T cells responses in T. cruzi infection. Chronic Chagas' disease Cardiomyopathy (CCC) is the most frequent and severe consequence of the chronic infection by protozoan parasite T. cruzi. Patients with CCC develop high levels of antibodies against ribosomal P proteins of T. cruzi, called P2β and P0. These antibodies can cross-react with, and stimulate, the β1-adrenergic and M2 muscarinic cardiac receptors, inducing a functional and pathological response in cardiomyocytes. In this study, we focused on the cellular immune response developed by CCC patients in response to T. cruzi ribosomal P proteins. Peripheral blood mononuclear cells (PBMC) from CCC patients stimulated with both proteins neither proliferated nor induced the expression of activation markers on CD4+ and CD8+ T cells. However, these cells responded by the secretion of IL-10, TNF-α and GM-CSF, giving evidence that there is indeed a pool of specific T cells in the periphery responsive to these proteins. Interestingly, the cytokines profile was not related with those described to whole parasite lysate or other recombinant proteins, suggesting that each parasite protein may contribute differently to the complex immune response developed in patients with Chagas' disease.